Cephalon granted H. Lundbeck exclusive Canadian rights to Nuvigil , Treanda, and Trisenox, and exclusive Canadian and Latin American rights to Provigil and Fentora buccal tablets

Cephalon Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

H. Lundbeck A/S

Denmark / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced